Body fat distribution may determine insulin resistance and its metabolic syndrome in humans, independent of obesity. Surgical removal of visceral fat (VF) in obese rats was associated with decreased leptin plasma levels and its gene expression in subcutaneous fat (SC). Chronic leptin treatment to rats decreased VF speci®cally supporting the role of leptin in determining fat distribution. Surgical removal of selected VF provided direct evidence of improved in vivo insulin action on hepatic glucose production (HGP) by over 2-fold vs sham-operated control. The impact of decreased VF on improved in vivo insulin action was further supported by obtaining similar decreases in VF by treating rats with leptin (Lep), b b3-aderenoreceptor agonist, or by severe caloric restriction (CR). All these three interventions improved insulin action on the modulation of HGP and were mostly attributed to preservation of hepatic glycogen stores. Because free fatty acids (FFA) plasma levels were unchanged, this effect may not be mediated portally by substrates. Improved peripheral insulin sensitivity and glycogen synthesis was demonstrated only in Lep. These data suggest that VF is a major determinant of hepatic insulin action. In obese rats, the ability of leptin to prevent visceral adiposity and its own expression is attenuated. Thus, the failure of leptin to regulate fat distribution and its own secretion suggest that`leptin resistance' may be a pathologic feature in obesity.
Introduction
Visceral adiposity is a major risk factor for insulin resistance and the metabolic syndrome. 1, 2 However, the covariance of visceral adiposity and insulin resistance may also be due to tightly associated hormonal or metabolic parameters. The fat-derived peptide leptin has important metabolic actions on energy expenditure, substrate partitioning, insulin action and storage of body fat. 3, 4 Moreover, it selectively decreases visceral adiposity and increases both hepatic and peripheral insulin actions. 5 To better understand the signi®cance of the relationship of fat distribution and leptin and their effects on insulin action, this article highlights the: (1) novel role of leptin in the regulation of fat distribution; (2) the impact of visceral fat (VF) on in vivo insulin action; and (3) the role of the leptin axis and fat distribution in the pathophysiology of obesity and insulin resistance.
Regulation of fat distribution
Obese individuals and rodents have marked elevations of plasma leptin directly related to increased fat mass (FM). 6, 7 Conversely, leptin treatment of obaob mice decreased food intake, body weight and FM through distinct hypothalamic pathways. 3, 4, 6, 8 Leptin also exhibits diurnal variation, increasing after food intake during the day and peaking at 2 am. 9 One possible mechanism for coupling nutrient sensing to leptin gene expression is the hexosamine biosynthetic pathway. This pathway, which accounts for a small percentage of glucose¯ux that is not committed to glycogen synthesis or glycolysis, is an ideal candidate for a cellular nutrient`sensor' responding to energy availability and mediating many metabolic effects. 10 Indeed, increased availability of glucose and free fatty acids (FFA) was shown to induce peripheral insulin resistance through this pathway. Recently, we demonstrated that leptin gene expression in adipose and muscle tissues is increased with increased¯ux through this pathway. 11 Leptin as well as the gene expression of plasminogen activating inhibitor-1 (PAI-1) in subcutaneous fat (SC) increased in rats after a short-term increase in glucose uptake by physiologic hyperinsulinemia, while other fat-derived peptides such as TNFa and AdipoQ (Acrp 30) were unchanged ( Figure 1) . Thus, the hexosamine biosynthetic pathway may be responsible for the nutritional regulation of a variety of fat-derived peptides. Although there may be considerable increases in plasma levels of these peptides during the day, it is yet to be determined whether nutrient sensing is altered in obesity and is varied in different fat depots.
To determine the role of leptin on fat distribution, leptin treatment (Lep) was administered to maintain high physiologic levels (20 ± 30 ngaml) by osmotic minipumps for 8 days to obese rats. While total FM decreased similarly in the pair-fed control group (approximately half the caloric intake ad libitum fed), Lep led to a speci®c and marked decrease in visceral adiposity to 60%. 5 These results indicate that leptin selectively decreases visceral adiposity independently of food intake and may be a strong determinant of fat distribution.
The mechanism for the selective decrease in visceral adiposity by leptin is as yet unclear but may be due to the following possibilities. First, chronic leptin treatment increases b-oxidation thereby increasing the mobilization of fat. 18 This increased fat mobilization may preferentially occur in VF. Second, the b-adrenergic neuronal pathway may be activated by leptin because this pathway was suggested as a peripheral effector of leptin. 12 The use of the b-adrenoreceptor agonist CL-316,243 in rodents resulted in a greater reduction in VF than in total FM (by 60% and 10%, respectively) with no changes in food intake. 13 These effects may be attributed to increased energy expenditure and thermogenesis. 14 Third, there is evidence that visceral fat may be more susceptible to apoptosis that may be induced by leptin (unpublished data).
To enhance our understanding on the relationship between leptin and VF, surgical removal of epididymal and perinephric fat (VF 7 ) or sham operations (VF ) were performed in obese rats. This selective removal of VF ( 10% of total FM) decreased leptin gene expression by 2 ± 3-fold in SC and resulted in a similar decrease in plasma leptin levels. 15 Therefore, the regulation of fat distribution is bi-directional where leptin decreases in VF, and removal of VF decreases leptin gene expression.
Overall (Figure 2 ), while leptin gene expression and plasma levels increase in parallel with total FM, 1 leptin administration to rodents decreased VF more speci®cally. 2 Moreover, VF extraction resulted in a signi®cant decrease in leptin gene expression 3 that may lead to an increase in food intake and eventually an increase in FM. 4 Finally, leptin downregulates its own gene expression in fat in rats during short-term infusion of leptin. 5, 16 This autoregulation may then prevent inappropriate increases in relation to fat or nutrients.
Role of VF on in vivo insulin action
Visceral adiposity in humans is associated with peripheral and hepatic insulin resistance. 1, 2 To directly address the impact of VF on in vivo insulin action, a hepatic ± pancreatic clamp was performed to test whether hepatic insulin sensitivity improved after surgical removal of VF (VF 7 ). Somatostatin was infused to suppress endogenous insulin while the insulin infusion rate was continuously adjusted to maintain fasting plasma glucose. There was a decreased insulin requirement in VF 7 by more than 2-fold compared with VF to maintain fasting plasma glucose, indicating increased hepatic insulin sensitivity. 15 While chronic leptin infusion in rodents markedly decreased plasma insulin concentration, suggesting that leptin improved insulin action in vivo, 3,4,6 it was not determined whether this effect is secondary to leptin-induced changes in fat distribution. To delineate the contribution of leptin-induced changes in VF to the potent effects of leptin on in vivo insulin action, other interventions such as treatment with the badrenoreceptor agonist CL-316,243 and severe caloric restriction (CR) were utilized to achieve similar Figure 1 Gene expression of leptin, PAI-1, TNFa and AdipoQ in subcutaneous fat in obese and lean rats by RT-PCR analysis. Tissues were sampled after physiologic hyperinsulinemia (3 mUakgamin) for 3 h. Lane 1, after saline infusion to obese rats (control). Lanes 2 and 3, after physiologic hyperinsulinemia to obese and lean rats. decreases in VF and were compared to leptin treatment (Lep). 13 Decreased VF resulted in similar improvements in insulin action on hepatic glucose production (HGP) by more than 2-fold in all three interventions ( Figure 3A) . In a net sense, the decreased HGP in all these interventions was mostly due to preservation of glycogen stores.
It was suggested that the unique metabolic characteristic of VF might modulate hepatic glucose metabolism through a`portal' effect mediated by FFA and glycerol. However, the plasma concentrations of glycerol and FFA were unchanged in these three experimental models as well as in the VFcompared with VF , thereby rendering unlikely the potential role of the`portal' effects of these substrates to modulate liver glucose metabolism. Thus, another cross-talk' mechanism where VF produces insulin resistance on the liver may exist.
During physiologic hyperinsulinemia, the rate of tissue glucose uptake in the Lep improved by more than 60%, but not in other interventions ( Figure 3B ). This improvement in peripheral insulin action was accounted for by a 2-fold increase in the rate of glycogen synthesis. This unique effect of leptin on peripheral insulin sensitivity may be due to the`lipopenic' effect of leptin. 19 Indeed, leptin increased lipid oxidation and decreased intramyocellular lipid levels; 17, 20 changes that are closely associated with increased insulin sensitivity. These metabolic data strongly suggest that VF plays a central role in modulating hepatic insulin action while leptin's effect on peripheral insulin action cannot be solely explained on the basis of the accounted decrease in VF.
The role of the leptin axis and fat distribution in the pathophysiology of obesity and insulin resistance
In obese rats, the plasma leptin level increased by 6-fold and VF increased by 4-fold compared with lean rats. This is in sharp contrast with lean rats where VF decreased by 2 ± 3-fold when plasma leptin level was similarly elevated (Figure 4 ). This strongly suggests that obesity attenuates the ability of leptin to regulate body fat distribution, speci®cally to prevent visceral adiposity. Furthermore, leptin infusion (20 ± 30 ngaml) for a few hours dramatically decreased leptin gene expression in SC in lean rats but failed to decrease it similarly in obese rats ( Figure 5 ). 16 Thus,`leptin resistance' may be a pathologic feature in obesity.
In summary, obesity exaggerates leptin expression in adipose tissue but attenuates the ability of leptin to prevent visceral adiposity and to decrease its own , and obese rats (partial data from Barzilai et al. 5 In obese rats, the plasma leptin level increased by 6-fold and VF increased by 4-fold compared with lean rats. This is in sharp contrast with lean rats where VF decreased by 2 ± 3 fold when the plasma leptin level was similarly elevated, suggesting that obesity attenuates the ability of leptin to regulate body fat distribution, speci®cally to prevent visceral adiposity.
expression. The dysregulation of VF and leptin expression promote insulin resistance and its metabolic syndrome ( Figure 6 ). This present view on the regulation of body fat and insulin action validates the hazards of visceral adiposity in total fatness. Figure 5 Gene expression of AdipoQ and leptin in subcutaneous fat in lean and obese rats by RT-PCR analysis. Tissues were sampled at the completion of the 6 h in vivo study. Lanes 1 and 2, after infusion of saline (control). Lanes 3 and 4 after infusion of high physiologic dose of leptin (20 ± 30 ngaml). 16 Figure 6 Schema for pathophysiology of`leptin resistance' in obesity, illustrating the postulated relationship between the leptin axis (Leptin), fat mass (FM) and visceral fat (VF) in obesity and insulin resistance. Obesity exaggerates leptin expression in adipose tissue but attenuates the ability of leptin to prevent visceral adiposity and to decrease its own expression. The dysregulation of VF and leptin expression promotes insulin resistance and its metabolic syndrome.
